| Description |
Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human AChE/BChE, with IC50s of 20.40 µM and 10.21 µM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent[1].
|
| Related Catalog |
|
| Target |
IC50: 20.40 µM (AChE), 10.21 µM (BChE)[1]
|
| In Vitro |
Geissoschizoline(1 μM; 48 hours) significantly reduces production of TNF-α and NO in LPS-stimulated microglial cells [1]. Geissoschizoline(1, 10 and 30 μM; 24 hours) shows no cytotoxicity to LPS-stimulated microglial cells[1] Cell Viability Assay[1] Cell Line: LPS-stimulated microglial cells (pre-incubated with various concentrations (0.1- 10 μM) of geissoschizoline for 1 hour) Concentration: 1 μM Incubation Time: 48 hours Result: Reduced neuroinflammation and increased neuroprotection, also restored synaptic transmission. Cell Cytotoxicity Assay[1] Cell Line: LPS-stimulated microglial cells Concentration: 1, 10 and 30 μM Incubation Time: 24 hours Result: Did not affect cell viability.
|
| References |
[1]. Josélia A Lima, et al. Geissoschizoline, a promising alkaloid for Alzheimer's disease: Inhibition of human cholinesterases, anti-inflammatory effects and molecular docking. Bioorg Chem. 2020 Nov;104:104215.
|
